Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM Olanzapine Depot vs Placebo in Acute Schizophrenia
NCT00088478Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of olanzapine in schizophrenia (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Positive and Negative Syndrome Scale Total Score at 8 weeks. Started Jun 2004; status: completed.
02
Drugs
olanzapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00088478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088478.